Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124I-M5A PET for Colorectal Liver Metastases
NCT03993327Phase 1Completed
- Sponsor
- City of Hope
- Start
- Jul 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of iodine i 124 monoclonal antibody m5a in colorectal cancer (CRC), sponsored by City of Hope. Primary endpoints: Tumor targeting pharmacokinetic parameters of iodine I 124 monoclonal antibody M5A at Day 6 and Percent of known liver lesions identified on iodine I-124 M5A imaging at 1 year. Started Jul 2020; status: completed.
02
Drugs
iodine i 124 monoclonal antibody m5a
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03993327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993327.